Journal Information
Vol. 10. Issue 4.
Pages 305-317 (July - August 2004)
Share
Share
Download PDF
More article options
Vol. 10. Issue 4.
Pages 305-317 (July - August 2004)
ARTIGO DE REVISÃO /REVISION ARTICLE
Open Access
Pleurodese
Pleurodesis
Visits
18434
Ricardo Melo*, J. Rosal Gonçalves**
* Interno do Complementar de Pneumologia, Serviço de Pneumologia do Hospital de Santa Maria Avenida Prof. Egas Moniz - 1699 Lisboa Codex - Portugal
** Assistente Hospitalar Graduado de Pneumologia, Serviço de Pneumologia do Hospital de Santa Maria Avenida Prof. Egas Moniz - 1699 Lisboa Codex - Portugal
This item has received

Under a Creative Commons license
Article information
RESUMO

A pleurodese consiste na indução de um processo inflamatório na superfície pleural com vista ao encerramento do espaço pleural. Os mecanismos exactos da pleurodese não estão completamente esclarecidos e existem várias controvérsias relacionadas com a mesma. A pleurodese pode ser realizada por introdução de agente esclerosante na cavidade pleural através de drenagem torácica; através da toracoscopia médica; através da videotoracoscopia; ou através da toracotomia. Os agentes químicos esclerosantes principais são o talco e as tetraciclinas. As indicações para pleurodese são o derrame pleural maligno recorrente, o pneumotórax primário recorrente, o pneumotórax secundário e o derrame pleural benigno refractário à terapêutica médica. Existem, contudo, algumas contra-indicações para a sua realização. As complicações graves da pleurodese são raras e dependem da técnica e do agente esclerosante usados.

O modo como é feita a pleurodese vai depender da experiência e das disponibilidades locais. Os autores fazem uma revisão sobre o tema da pleurodese.

REV PORT PNEUMOL 2004; X (4): 305-317

Palavras-chave:
pleurodese
derrame pleural
pneumotórax
indicações
contra-indicações
agentes esclerosantes
ABSTRACT

Pleurodesis is a way of inducting an inflammatory process in the pleural surface in order to create the closure of the pleural space. The exact mechanism isn’t completely understood and there is still a great deal of controversy concerning pleurodesis. Pleurodesis can be achieved by introduction of a sclerosant agent trough a chest tube into the pleural space, by medical thoracoscopy, by surgical thoracoscopy or by thoracotomy. The principal esclerosant agents are talc and tetracycline. The indications for pleurodesis are malignant recurrent pleural effusion, primary recurrent pneumothorax, secondary pneumothorax and benign pleural effusion resistant to medical treatment. There are, although, some contraindications to performing it. Serious complications of pleurodesis are rare and depend on the technique and agent used. The method of choice for pleurodesis is related to the experience and technical facilities available. The author presents a review about pleurodesis.

REV PORT PNEUMOL 2004; X (4):

Key-words:
pleurodesis
pleural effusion
pneumothorax
indications
contraindications
sclerosant agents
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
Pleural Diseases.
LoddenKemper. Eur Respir Mono, 7 (2002), pp. 1-326
[2.]
C. Kroegel, V.B. Antony.
Immunology of pleural inflammation: potencial implications for pathogenesis, diagnosis and therapy.
Eur Respir J, 10 (1997), pp. 2411-2418
[3.]
G. Antunes, E. Neville, J. Duffy, et al.
BTS guidelines for the management of malignant pleural effusions.
Thorax, 58 (2003), pp. ii29-ii38
[4.]
J. Rosal Gonçalves.
A pleurodese, quando e como? Em: Monografia do 34º Curso de Pneumologia para pós-graduados, Clinica de Pneumologia, FML/HSM, pp. 129-137
[5.]
S. Sahn.
Pleural diseases related to metastatic malignancies.
Eur Respir J, 10 (1997), pp. 1907-1913
[6.]
R.W. Light, V.S. O’Hara, T.E. Moritz, et al.
Intrapleural Tetracycline for the Prevention of Recurrent Spontaneous Pneumothorax. Results of a Department of Veterans Affairs Cooperative Study.
JAMA, 264 (1990), pp. 2224-2230
[7.]
R.J. Karman.
Thoracoscopy.
Pulmonary/Respiratory Therapy Secrets, 2, pp. 91-95
[8.]
J.R. Viallat, F. Rey, P. Astoul, et al.
Thoracoscopic talc poudrage pleurodesis for malignant effusions.
Chest, 110 (1996), pp. 1387-1393
[9.]
V.B. Antony, R. Loddenkemper, P. Astoul, et al.
Management of malignant pleural effusions.
Eur Respir J, 18 (2001), pp. 402-419
[10.]
G. Miserocchi.
Physiology and pathophysiology of pleural fluid turnover.
Eur Respir J, 10 (1997), pp. 219-225
[11.]
A. Sanchez-Armengol, O.F. der Rodriguez-Pana.
Survival and talc pleurodesis in metastatic pleural carcinoma, revisited: report on 125 cases.
Chest, 104 (1993), pp. 1482-1485
[12.]
F. Rodriguez-Panadero, R.S. Gil, J.M. Juan, et al.
Prediction of results of talc pleurodesis in malignant pleural effusions.
Am J Respir Crit Care Med, 149 (1994), pp. 2
[13.]
F. Rodriguez-Panadero.
Derrames pleurales malignos.
Rev Port Pneumol, 1 (1995), pp. 25-31
[14.]
F. Rodriguez-Panadero, V.B. Anthony.
Pleurodesis: state of the art.
Eur Respir J, 10 (1997), pp. 1648-1654
[15.]
F. Rodriguez-Panadero, J. Lopez Mejias.
Low glucose and pH levels in malignant pleural effusion: diagnostic significance and prognostic value in respect to pleurodesis.
Am Rev Respir Dis, 139 (1989), pp. 663-667
[16.]
Y. Aelony.
Treatment of mesotheliomatous pleural effusion. Experimental therapy versus thoracoscopy talc poudrage?.
J Bronchol, 8 (2001), pp. 54-59
[17.]
B. Parente.
Tópicos especiais.
Tratado de Pneumologia, pp. 1201-1205
[18.]
Clinical Oncology, 2, pp. 930-934
[19.]
G.T. Kinasewitz.
Transudative effusions.
Eur Respir J, 10 (1997), pp. 714-718
[20.]
C. Sudduth, S.A. Sahn.
Pleurodesis for non-malignant pleural effusions. Recommendations.
Chest, 102 (1992), pp. 1855-1860
[21.]
G. Hillerdal.
Chylothorax and pseudochylothorax.
Eur Respir J, 10 (1997), pp. 1157-1162
[22.]
R.W. Ligth, H. Hamm.
Pleural disease and acquired immune deficiency syndrome.
Eur Respir J, 10 (1997), pp. 2638-2643
[23.]
J. Ferrer.
Pleural tuberculosis.
Eur Respir J, 10 (1997), pp. 942-947
[24.]
H. Hamm, R.W. Ligth.
Parapneumonic effusion and empyema.
Eur Respir J, 10 (1997), pp. 1150-1156
[25.]
M. Henry, T. Arnold, J. Harvey.
BTS guidelines for the management of spontaneous pneumothorax.
Thorax, 58 (2003), pp. ii39-ii52
[26.]
F.M.N.H. Schramel, P.E. Postmus, R.G.J.R.A. Vanders Chueren.
Current aspects of spontaneous pneumothorax.
Eur Respir J, 10 (1997), pp. 1372-1379
[27.]
M. Noppen.
Management of primary spontaneous pneumothorax: does cause matter?.
Monaldi Arch Chest Dis, 56 (2001), pp. 344-348
[28.]
J.I. Peters.
Pneumothorax.
Pulmonary Diseases and Disorders, 3, pp. 1447-1450
[29.]
L. Noronha, J. Roldão Vieira.
Pneumotórax espontâneo.
Tratado de Pneumologia, pp. 1497-1503
[30.]
W.G. Gobel, W.G. Rhea, I.A. Nelson, et al.
Spontaneous pneumothorax.
J Thorac Cardiovasc Surg, 46 (1963), pp. 331-345
[31.]
M. Almind, P. Lange, K. Viskum.
Spontaneous pneumothorax: comparison of simple drainage, talc pleurodesis and tetracycline pleurodesis.
Thorax, 44 (1989), pp. 627-630
[32.]
G. Cardillo, F. Facciolo, R. Giunti, et al.
Videothoracoscopy Treatment of Primary Spontaneous Pneumothorax: A 6-Year Experience.
Ann Thorac Surg, 69 (2000), pp. 357-362
[33.]
M.H. Baumann, C. Strange, J.E. Heffner, et al.
Management of Spontaneous Pneumothorax. An American College of Chest Physicians Delphi Consensus Statement.
Chest, 119 (2001), pp. 590-602
[34.]
P. Bastos, J. Casanova, L. Gonçalves, et al.
Tratamento do pneumotórax espontâneo por videotoracoscopia.
Rev Port Pneumol, 4 (1998), pp. 287-293
[35.]
H.G. Colt, P.N. Mathur.
Manual of Pleural Procedures, pp. 155-175
[36.]
J. Milanez, F. Vargas, L. Filomeno, et al.
Intrapleural talc for the prevention of recurrent pneumothorax.
Chest, 106 (1994), pp. 1162-1165
[37.]
R. Loddenkemper.
Thoracoscopy-state of the art.
Eur Respir J, 11 (1997), pp. 213-221
[38.]
M.A. Wait, A. Estrera.
Changing Clinical Spectrum of Spontaneous Pneumothorax.
American Journal of Surgery, 164 (1992), pp. 528-530
[39.]
S. Sahn, J.E. Heffner.
Spontaneous Pneumothorax.
[40.]
J.T. Van Winter, F.C. Nichols III, P.C. Pairolero, et al.
Management of Spontaneous Pneumothorax During Pregnacy: Case Report and Review of the Literature.
Mayo Clin Proc, 71 (1996), pp. 249-252
[41.]
D. Bouros, M. Froudarakis, N.M. Siafakas.
Pleurodesis. Everything flows.
Chest, 118 (2000), pp. 577-579
[42.]
Cancer Principles and Pratice Oncology, 6, pp. 2731-2735
[43.]
S. Sahn.
Malignant Pleural Effusions.
Pulmonary Diseases and Disorders, 3, pp. 1436-1437
[44.]
R.W. Light.
Pleural Diseases, 4th edition, pp. 118-130
[45.]
C.A. Olivares-Torres, R. Laniado-Laborin, C. Chávez-Garcia, et al.
Iodopovidone Pleurodesis for Recurrent Pleural Effusions.
Chest, 122 (2002), pp. 581-583
[46.]
S. Sahn.
Is Talc Indicated for Pleurodesis? Pro: Talc Should Be Used for Pleurodesis.
J Bronchol., 9 (2002), pp. 223-227
[47.]
R.W. Light.
Is Talc Indicated for Pleurodesis? Con: Talc Should Not Be Used for Pleurodesis.
J Bronchol., 9 (2002), pp. 228-231
[48.]
P. Astoul.
Pleurodesis for the Therapy of Malignant Pleural Effusions. Should It Be an Inpatient Procedure? Pro: Inpatient Procedure.
J. Bronchol., 10 (2003), pp. 215-217
[49.]
D. Sterman, R. Kruklitis, M. Lund, A. Musani.
Pleurodesis for the Therapy of Malignant Pleural Effusions. Should It Be an Inpatient Procedure? Con: Inpatient Procedure.
J. Bronchol., 10 (2003), pp. 218-222
[50.]
J. Roldão Vieira.
Tumores da pleura.
Tratado de Pneumologia, pp. 1489-1493
[51.]
R.W. Ligth.
Diagnostic principles in pleural disease.
Eur Respir J, 10 (1997), pp. 476-481
[52.]
R. Berger.
Pleurodesis for spontaneous pneumothorax. Will the procedure of choice please stand up?.
Chest, 106 (1994), pp. 992-994
[53.]
D.A. Waller, J. Forty, A.K. Sony, et al.
Video-thoracoscopic operation for secondary spontaneous pneumothorax.
Ann Thorac Surg, 57 (1994), pp. 1612-1615
Copyright © 2004. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?